Ricevi le ultime notizie sulle azioni Immutep con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di IMMP

Ultime notizie per

Immutep

Immutep Limited - American Depositary Shares

Immutep Ltd

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Avalo Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Candel Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

C4 Therapeutics

Editas Medicine

ETHZilla

Foghorn Therapeutics

Humacyte

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Palisade Bio

Puma Biotechnology

Pyxis Oncology

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Tenaya Therapeutics

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Immutep (IMMP) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Vendite allo scoperto

Rapporto azionario

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Comments

Immutep Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO